Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

542 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M. Thiel E, et al. Among authors: kanz l. Lancet Oncol. 2010 Nov;11(11):1036-47. doi: 10.1016/S1470-2045(10)70229-1. Epub 2010 Oct 20. Lancet Oncol. 2010. PMID: 20970380 Clinical Trial.
German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma.
Herrlinger U, Schabet M, Brugger W, Kortmann RD, Küker W, Deckert M, Engel C, Schmeck-Lindenau HJ, Mergenthaler HG, Krauseneck P, Benöhr C, Meisner C, Wiestler OD, Dichgans J, Kanz L, Bamberg M, Weller M. Herrlinger U, et al. Among authors: kanz l. Ann Neurol. 2002 Feb;51(2):247-52. doi: 10.1002/ana.10102. Ann Neurol. 2002. PMID: 11835382 Clinical Trial.
Meeting report: primary central nervous system lymphoma: standards of care and future perspectives.
Herrlinger U, Korfel A, Hebart H, Schlegel U, Plasswilm L, Illerhaus G, Finke J, Krüger W, Montemurro M, Wolf T, Thiel E, Bamberg M, Weller M, Kanz L; Centers for Neuro-Oncology and Lymphoma, University of Tubingen, Germany. Herrlinger U, et al. Among authors: kanz l. Onkologie. 2005 Feb;28(2):109-11. doi: 10.1159/000083374. Epub 2005 Feb 3. Onkologie. 2005. PMID: 15692223
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.
Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrman M, Hochhaus A, Hasford J, Hehlmann R, Saußele S; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK). Proetel U, et al. Ann Hematol. 2014 Jul;93(7):1167-76. doi: 10.1007/s00277-014-2041-0. Ann Hematol. 2014. PMID: 24658964 Free PMC article. Clinical Trial.
The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia.
Both A, Krauter J, Damm F, Thol F, Göhring G, Heuser M, Ottmann O, Lübbert M, Wattad M, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Brugger W, Schlegelberger B, Heil G, Ganser A, Wagner K. Both A, et al. Among authors: kanz l. Ann Hematol. 2017 Jun;96(6):895-904. doi: 10.1007/s00277-017-2967-0. Epub 2017 Mar 22. Ann Hematol. 2017. PMID: 28331964
542 results